Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 plus bevacizumab versus bevacizumab for first-line maintenance treatment of epithelial ovarian cancer
CTR20263171Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan, bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Sep 2026; status: active.
02
Drugs
trastuzumab rezetecanbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20263171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263171.